Discovers, develops and commercializes oncology and endocrine therapies to treat a variety of conditions, principally cancer. The company's lead product is Cetrotide®, a luteinizing hormone releasing hormone (LHRH) antagonist approved for in vitro fertilization. Products under development include Perofosine for the treatment of multiple myeloma and colorectal cancer (Phase III) and Solorel™ (AEZS-130), a diagnostic for the diagnosis of adult growth hormone deficiency (Phase III).